On August 29, 2023, the Centers for Medicare & Medicaid Services (CMS) disclosed the ten Medicare Part D drugs chosen for the premiere series of negotiations of the Medicare Drug Price Negotiation Program. Notably, the announcement arrived a handful of days before the September 1, 2023, statutory deadline imposed by the Inflation Reduction Act (IRA). The drugs’ negotiated prices are slated to come into play in 2026 as per the details revealed by Epstein Becker & Green. For more, refer to the original report.
This governmental action forms part of a broader strategy to control drug prices, against the backdrop of a typical American’s concerns about escalating healthcare costs. The IRAs implementation and the commencement of its Medicare Drug Price Negotiation Program indicate a focused effort to address these issues.
While critics argue about potential impacts on innovation, advocates for the CMS and the Congress-instigated program believe this step will be a key element in unlocking lower drug prices for Medicare beneficiaries. However, one must remember that this is not a swift process – the effect of the negotiated prices will not be felt by the public until 2026, as stated by the CMS.
This is a significant development for legal professionals